Smoldering Multiple Myeloma (SMM) is a plasma cell disorder that is asymptomatic and considered pre-malignant, with risks of progression to myeloma. Diagnosis follows the 2014 IMWG criteria, requiring specific monoclonal protein levels and plasma cell percentages. It is essential to rule out organ damage and malignancy biomarkers. SMM is often found incidentally during routine checkups, and while tests are accessible in urban areas, challenges remain in remote locations.

AI has been used for both descriptions and subtitles, even though it has been checked, there may be errors.